Invalidity dossier
US 10889632
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/16/2026, 7:13:31 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US10889632B2
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent number: US10889632B2
Application number: US16/527,836
Inventor(s): Antonio Lanzavecchia; Annalisa Macagno
Assignee: Institute for Research in Biomedicine IRB (original and current assignee, per the listed data)
Key dates:
- Prior art date: 2008-07-16
- Filing date: 2019-07-31
- Publication of US20200017575A1: 2020-01-16
- Grant/publication date: 2021-01-12
- Anticipated expiration: 2029-07-15
- Legal status: Expired – Fee Related
Other version: US20200017575A1
Purpose and plain-language scope (from the supplied text):
The patent concerns human cytomegalovirus (HCMV) neutralizing antibodies and their use. The classifications place it in the antibody field (C07K16/00) directed against viruses (C07K16/08), specifically Cytomegalovirus (C07K16/089), and in antiviral medicinal preparations (A61P31/20, A61P31/22; A61K39/42). Classifications also reference antibody fragments (Fab, F(ab')2, Fv, scFv), CDRs, human (primate) origin, glycosylation, and neutralization/antagonist effect on antigen. The prior-art keywords listed are: antibody, seq, antibodies, hcmv, epitope.
What the supplied excerpt does not establish:
The excerpt provides no claims text, no sequence listing, no exemplary antibody names, no epitope residues, no experimental data (e.g., neutralization titers), no dosages or formulations, no examples, and no written description. It therefore cannot establish the precise scope of any claim, the specific antibodies or sequences covered, or the therapeutic methods claimed. The title, classification entries, and assignee/status data are metadata and are not a legal conclusion on claim coverage, validity, or enforceability. The "Expired – Fee Related" status is stated as an assumption in the source and is not a legal determination. No litigation, ownership-transfer, validity, or prior-art analysis is made here.
Source: https://patents.google.com/patent/[US10889632](/patent/US10889632)/en
Generated 10/1/2026, 10:03:26 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10889632. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.